Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as first line chemotherapy for patients with unresectable advanced esophageal cancer in Japan
Sign Up to like & getrecommendations! Published in 2025 at "Esophagus"
DOI: 10.1007/s10388-025-01144-5
Abstract: Although pembrolizumab plus chemotherapy (Pembro + Chemo) is the recommended first-line therapy for advanced esophageal cancer, it remains unclear whether it is more cost-effective than chemotherapy (Chemo). We evaluated the cost-effectiveness of Pembro + Chemo versus Chemo from a… read more here.
Keywords: chemo; analysis; chemotherapy; pembro chemo ... See more keywords
Abstract PS14-08: Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-ps14-08
Abstract: Background: In KEYNOTE-355 (NCT02819518), pembrolizumab (pembro) + chemotherapy (chemo) led to statistically significant and clinically meaningful improvements in PFS and OS (primary endpoints) vs placebo (pbo) + chemo in patients (pts) with previously untreated PD-L1… read more here.
Keywords: plus chemotherapy; chemotherapy; pembro chemo; safety ... See more keywords
Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-lb1-07
Abstract: Background: In the phase 3 KEYNOTE-522 (NCT03036488) study, neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) with adjuvant pembro significantly improved pCR, event-free survival (EFS) and OS vs neoadjuvant placebo (pbo) + chemo with adjuvant pbo in… read more here.
Keywords: pbo chemo; chemo; pembrolizumab; pembro chemo ... See more keywords
Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.4073
Abstract: 4073 Background: Pathologic tumor downstaging (pDS) is more accurate than clinical staging for prognosis; generally, patients (pts) with downstaged tumors have lower recurrence rates and improved overall survival (OS). mPR is an important surrogate end… read more here.
Keywords: chemo; pbo chemo; pbo; keynote 585 ... See more keywords
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.3_suppl.345
Abstract: 345 Background: First-line (1L) treatment of GEJC and EAC is similar to that for gastric adenocarcinomas, based on evidence from 2 large phase 3 gastric and esophageal cancer trials. The phase 3 KEYNOTE-590 trial (NCT03189719)… read more here.
Keywords: chemo; pembro chemo; keynote 590; keynote 859 ... See more keywords
KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.4036
Abstract: 4036 Background: In the phase 3KEYNOTE-859 study (NCT03675737), first-linepembrolizumab (pembro) + chemotherapy (chemo) continued to provide longer OS (HR, 0.79; 95% CI, 0.71-0.88) and PFS (HR, 0.76; 95% CI, 0.68-0.85), and a higher ORR (51.0%… read more here.
Keywords: chemo; her2 negative; pembro chemo; gej adenocarcinoma ... See more keywords